Neurognostics: Elects New Board Member

Douglas M. Tucker, PhD, MBA
Neurognostics, Inc.

Phone: 414-727-7950 x 110
Fax: 414-727-7952
E-mail: [email protected]

Milwaukee, WI, August 29, 2005 – Neurognostics, Inc., the leader in functional Magnetic Resonance Imaging (fMRI) products and services, is pleased to announce the election of Milton Silva-Craig to its Board of Directors. Mr. Silva-Craig will begin his service as a Board Director as of the next regularly scheduled Board meeting.

Mr. Silva-Craig is the President and Chief Operating Officer of Emageon Inc., (NASDAQ: EMAG). Mr. Silva-Craig joined Emageon in March, 2001 as its COO. Emageon provides enterprise-based, medical image management software and services. Prior to joining Emageon, Mr. Silva-Craig held key leadership positions in marketing and sales, business development, product development and operations during his eight years at General Electric Medical Systems, a leading provider of medical diagnostic imaging equipment and information technologies. Mr. Silva-Craig holds a BA in International Relations, an MBA in International Business and Marketing, and a JD in Corporate Law from the University of Wisconsin – Madison.

“Milton has a tremendous track record in the field of medical imaging, both in a multi-national setting and most recently with a successful start-up organization. His experience, knowledge and demonstrated success in the field are great assets. I’m excited at the prospect of working with him and certain that he will be able to make significant contributions to the company’s success,” said Jeff Rusinow, Neurognostics’ Board Chairman.

Founded in 2003, Neurognostics strives to enhance the quality of life for millions of patients suffering from disorders of the central nervous system (CNS) by developing, validating, and implementing applications that release the clinical power of fMRI. fMRI is a powerful imaging technique that extends the capability of Magnetic Resonance (MR) imaging by providing information about the functioning of imaged tissue. The Company strives to develop applications that will become the standard technique to assess and manage patients suffering from a variety of CNS disorders.